Eledon Pharmaceuticals Inc (FRA:2TK)

€ 2.4 0.02 (0.84%) Market Cap: 98.19 Mil Enterprise Value: 58.42 Mil PE Ratio: 0 PB Ratio: 0.91 GF Score: 36/100

Eledon Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q1 2023 Eledon Pharmaceuticals Inc Earnings Call Transcript
May 11, 2023

€2.52 (-4.55%)

Earnings
Q4 2022 Eledon Pharmaceuticals Inc Earnings Call Transcript
Mar 30, 2023

€2.18 (+4.81%)

Earnings
Eledon Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
Q3 2022 Eledon Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2022

€2.58 (+8.40%)

Earnings
Eledon Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript
Sep 29, 2022
Eledon Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Eledon Pharmaceuticals Inc at Gilmartin Group Inaugural Emerging Growth Company Showcase (Virtual) Transcript
Aug 31, 2022
Q2 2022 Eledon Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2022

€3.28 (+1.86%)

Earnings
Eledon Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022
Q1 2022 Eledon Pharmaceuticals Inc Earnings Call Transcript
May 12, 2022

€2.44 (+0.83%)

Earnings
Eledon Pharmaceuticals Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
Apr 21, 2022
Q4 2021 Eledon Pharmaceuticals Inc Earnings Call Transcript
Mar 24, 2022

€3.38 (+3.68%)

Earnings
Q3 2021 Eledon Pharmaceuticals Inc Earnings Call Transcript
Nov 11, 2021

€4.22 (-1.40%)

Earnings
Q2 2021 Eledon Pharmaceuticals Inc Earnings Call Transcript
Aug 12, 2021

€5.5 (+2.80%)

Earnings
Q1 2021 Eledon Pharmaceuticals Inc Earnings Call Transcript
May 13, 2021

€7.6 (-2.56%)

Earnings
Eledon Pharmaceuticals Inc at NobleCon Investor Conference (Virtual) Transcript
Jan 20, 2021

Eledon Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript

Sep 29, 2022 / 06:30PM GMT

Release Date Price: €2.8 (-2.10%)

Transcript

Matt Kaplan

Ladenburg Thalmann & Co. Inc - MD - Healthcare Research

I'm Matt Kaplan with Ladenburg. And it's my pleasure to introduce our next presenting company, Eledon. Presenting for Eledon today is the CEO, DA Gros; and also Steve Perrin as well, the Chief Scientific Officer.

Maybe first, you can give us just a little bit of a background overview if people aren't familiar with Eledon, just a background on the company and what you're focused on.

DA Gros

Eledon Pharmaceuticals, Inc. - CEO

Sure. So first, it's a pleasure to be here. Thank you very much for having invited us. We'll be -- I'd like to remind you we'll be making forward-looking statements. So please review our disclaimers in our public filings.

Eledon is focused on the development of anti-CD40 ligand antibodies. Our primary focus is around immunology. Today, our lead asset tegoprubart has completed a Phase 2 in ALS. And we have ongoing study in kidney transplantation, islet cell transplantation, and IgA Nephropathy.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.